Shandong Xinhua Pharmaceutical (000756.SZ) Obtains Drug Registration Certificate for Alendronate Sodium Oral Solution

Stock News10-31

Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the Drug Registration Certificate for Alendronate Sodium Oral Solution (hereinafter referred to as "the Product") issued by the National Medical Products Administration. The Alendronate Sodium Oral Solution is indicated for the treatment of osteoporosis in postmenopausal women to prevent hip and vertebral fractures (vertebral compression fractures), as well as to increase bone mass in men with osteoporosis. According to relevant statistics, the sales of Alendronate Sodium in 2024 across three major channels—including Chinese public hospitals, primary medical institutions, and retail pharmacies—reached RMB 720 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156550056?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156550056","market":"sh","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical (000756.SZ) Obtains Drug Registration Certificate for Alendronate Sodium Oral Solution","media":"Stock News","content":"<p>Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the Drug Registration Certificate for Alendronate Sodium Oral Solution (hereinafter referred to as \"the Product\") issued by the National Medical Products Administration. The Alendronate Sodium Oral Solution is indicated for the treatment of osteoporosis in postmenopausal women to prevent hip and vertebral fractures (vertebral compression fractures), as well as to increase bone mass in men with osteoporosis. According to relevant statistics, the sales of Alendronate Sodium in 2024 across three major channels—including Chinese public hospitals, primary medical institutions, and retail pharmacies—reached RMB 720 million.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical (000756.SZ) Obtains Drug Registration Certificate for Alendronate Sodium Oral Solution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical (000756.SZ) Obtains Drug Registration Certificate for Alendronate Sodium Oral Solution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-31 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the Drug Registration Certificate for Alendronate Sodium Oral Solution (hereinafter referred to as \"the Product\") issued by the National Medical Products Administration. The Alendronate Sodium Oral Solution is indicated for the treatment of osteoporosis in postmenopausal women to prevent hip and vertebral fractures (vertebral compression fractures), as well as to increase bone mass in men with osteoporosis. According to relevant statistics, the sales of Alendronate Sodium in 2024 across three major channels—including Chinese public hospitals, primary medical institutions, and retail pharmacies—reached RMB 720 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000756","symbol_name":"新华制药","start_time":0,"source_url":"","article_id":"1156550056","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156550056","pubTimestamp":1761900381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the Drug Registration Certificate for Alendronate Sodium Oral Solution (hereinafter referred to as \"the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"000756":"新华制药","BK0239":"医药制造","BK0164":"国企混改"},"translate_title":"山东新华制药（000756.SZ）获得阿仑膦酸钠口服溶液药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000756":1},"content_text":"Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the Drug Registration Certificate for Alendronate Sodium Oral Solution (hereinafter referred to as \"the Product\") issued by the National Medical Products Administration. The Alendronate Sodium Oral Solution is indicated for the treatment of osteoporosis in postmenopausal women to prevent hip and vertebral fractures (vertebral compression fractures), as well as to increase bone mass in men with osteoporosis. According to relevant statistics, the sales of Alendronate Sodium in 2024 across three major channels—including Chinese public hospitals, primary medical institutions, and retail pharmacies—reached RMB 720 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156550056","isCrawlerRequest":true}